Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 subcutaneous phase 2/3 study in adults with bullous pemphigoid
MOH_2022-07-19_011920Phase 3Not yet recruiting
- Sponsor
- argenx
- Start
- Jun 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Bullous Pemphigoid (BP) comparing Efgartigimod PH20 with Placebo (2 arms). Primary endpoint: Sustained remission on therapy. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on MOH_2022-07-19_011920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-19_011920.